1. Home
  2. ATNM vs LGL Comparison

ATNM vs LGL Comparison

Compare ATNM & LGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.10

Market Cap

36.8M

Sector

Health Care

ML Signal

HOLD

Logo LGL Group Inc. (The)

LGL

LGL Group Inc. (The)

N/A

Current Price

$6.85

Market Cap

40.9M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ATNM
LGL
Founded
2000
1917
Country
United States
United States
Employees
N/A
7
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
36.8M
40.9M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ATNM
LGL
Price
$1.10
$6.85
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.50
N/A
AVG Volume (30 Days)
132.5K
4.2K
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
14.17
N/A
EPS
N/A
N/A
Revenue
$90,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$42.61
Revenue Growth
11.11
N/A
52 Week Low
$0.95
$5.45
52 Week High
$1.95
$9.55

Technical Indicators

Market Signals
Indicator
ATNM
LGL
Relative Strength Index (RSI) 49.69 46.34
Support Level $1.02 $6.90
Resistance Level $1.25 $7.35
Average True Range (ATR) 0.07 0.21
MACD 0.01 -0.02
Stochastic Oscillator 55.24 35.29

Price Performance

Historical Comparison
ATNM
LGL

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About LGL LGL Group Inc. (The)

LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.

Share on Social Networks: